CR8376A - Metodo para producir derivados de (3-oxo-2,3-dihidro-1 h-isoindol-1-il)-acetilguanidina - Google Patents

Metodo para producir derivados de (3-oxo-2,3-dihidro-1 h-isoindol-1-il)-acetilguanidina

Info

Publication number
CR8376A
CR8376A CR8376A CR8376A CR8376A CR 8376 A CR8376 A CR 8376A CR 8376 A CR8376 A CR 8376A CR 8376 A CR8376 A CR 8376A CR 8376 A CR8376 A CR 8376A
Authority
CR
Costa Rica
Prior art keywords
isoindol
oxo
acetilguanidine
dihidro
derivatives
Prior art date
Application number
CR8376A
Other languages
English (en)
Inventor
Gerrit Schubert
Joerg Rieke-Zapp
Johannes Keil
Heinz-Werner Kleemann
Reda Hanna
Bao-Guo Huang
Xiao-Dong Wu
Yves Gouraud
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR8376A publication Critical patent/CR8376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion se refiere a metodos para producir derivados de (3-oxo-2,3-dihidro-1H-isoindol-1-il)-acetilguanidina de la formula (I) utilizando derivados de 3-hidroxi-2,3-dihidro-1H-isoindol-1-ona o derivados del ester acrilico de 3-(2-carbamoilfenilo) como fases intermedias, a un metodo de resolucion de racematos y a productos intermedios del metodo segun la invencion.
CR8376A 2003-12-02 2006-04-28 Metodo para producir derivados de (3-oxo-2,3-dihidro-1 h-isoindol-1-il)-acetilguanidina CR8376A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10356717A DE10356717A1 (de) 2003-12-02 2003-12-02 Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten

Publications (1)

Publication Number Publication Date
CR8376A true CR8376A (es) 2007-12-04

Family

ID=34638338

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8376A CR8376A (es) 2003-12-02 2006-04-28 Metodo para producir derivados de (3-oxo-2,3-dihidro-1 h-isoindol-1-il)-acetilguanidina

Country Status (38)

Country Link
EP (1) EP1692105B1 (es)
JP (1) JP4809774B2 (es)
KR (1) KR101202604B1 (es)
CN (1) CN100526297C (es)
AR (1) AR046733A1 (es)
AT (1) ATE395334T1 (es)
AU (1) AU2004295056B2 (es)
BR (1) BRPI0417147A (es)
CA (1) CA2548020C (es)
CR (1) CR8376A (es)
CY (1) CY1108187T1 (es)
DE (2) DE10356717A1 (es)
DK (1) DK1692105T3 (es)
EC (1) ECSP066597A (es)
EG (1) EG25498A (es)
ES (1) ES2304634T3 (es)
HK (1) HK1097525A1 (es)
HR (1) HRP20080253T3 (es)
IL (1) IL175834A (es)
JO (1) JO2498B1 (es)
MA (1) MA28220A1 (es)
MY (1) MY136467A (es)
NO (1) NO20063058L (es)
NZ (1) NZ547625A (es)
OA (1) OA13293A (es)
PA (1) PA8618701A1 (es)
PE (1) PE20051037A1 (es)
PL (1) PL1692105T3 (es)
PT (1) PT1692105E (es)
RS (1) RS50571B (es)
RU (1) RU2397159C2 (es)
SI (1) SI1692105T1 (es)
TN (1) TNSN06167A1 (es)
TW (1) TWI334348B (es)
UA (1) UA83883C2 (es)
UY (1) UY28648A1 (es)
WO (1) WO2005054195A1 (es)
ZA (1) ZA200603338B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
CA2725230C (en) * 2008-04-16 2016-05-17 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
CN107778238B (zh) * 2016-08-29 2022-07-22 中山大学 一种3，4-二氢异喹啉-1-酮的合成新方法
CN107286074B (zh) * 2017-08-16 2019-08-20 厦门华厦学院 3-羟基异吲哚-1-酮衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
DE10356717A1 (de) 2005-07-07
AU2004295056A1 (en) 2005-06-16
NO20063058L (no) 2006-06-30
UA83883C2 (en) 2008-08-26
KR101202604B1 (ko) 2012-11-19
HRP20080253T3 (en) 2008-09-30
MA28220A1 (fr) 2006-10-02
RS50571B (sr) 2010-05-07
TW200526207A (en) 2005-08-16
CN1886374A (zh) 2006-12-27
TWI334348B (en) 2010-12-11
CA2548020A1 (en) 2005-06-16
AR046733A1 (es) 2005-12-21
TNSN06167A1 (en) 2007-11-15
JP2007516243A (ja) 2007-06-21
KR20060111558A (ko) 2006-10-27
PT1692105E (pt) 2008-07-04
PE20051037A1 (es) 2005-12-29
ZA200603338B (en) 2007-06-27
UY28648A1 (es) 2005-06-30
EG25498A (en) 2012-01-22
CN100526297C (zh) 2009-08-12
PA8618701A1 (es) 2006-07-03
NZ547625A (en) 2010-01-29
RU2397159C2 (ru) 2010-08-20
AU2004295056B2 (en) 2011-04-14
WO2005054195A1 (de) 2005-06-16
CY1108187T1 (el) 2014-02-12
ES2304634T3 (es) 2008-10-16
RU2006123410A (ru) 2008-01-10
SI1692105T1 (sl) 2008-08-31
MY136467A (en) 2008-10-31
EP1692105A1 (de) 2006-08-23
PL1692105T3 (pl) 2008-09-30
JO2498B1 (en) 2009-10-05
IL175834A (en) 2010-12-30
EP1692105B1 (de) 2008-05-14
HK1097525A1 (en) 2007-06-29
OA13293A (en) 2007-01-31
CA2548020C (en) 2013-01-08
ATE395334T1 (de) 2008-05-15
DK1692105T3 (da) 2008-08-25
ECSP066597A (es) 2006-10-25
DE502004007177D1 (de) 2008-06-26
BRPI0417147A (pt) 2007-03-06
JP4809774B2 (ja) 2011-11-09
IL175834A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR062841A1 (es) Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos
NO20060544L (no) Enzymatiske prosesser for produksjon av 4-substituerte 3-hydroksysmorsyrederivater og naerliggende cyano, hydroksy substituerte karboksylsyre estere
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
DE602006013940D1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
GEP20074078B (en) Fluoro substituted cyclo-alkanoindoles, compositions comprising them and their use
CR7742A (es) Formulaciones para uso veterinario que contienen productos de origen no animal
TW200626580A (en) Synthesis of (5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
CY1108334T1 (el) Υποκατασταθεισες δικετοπιπεραζινες ως ανταγωνιστες ωκυτοκινης
EA201101015A1 (ru) Способ получения бивалирудина
EA200600197A1 (ru) Получение производных соединения 1,3-дифенилпроп-2-ен-1-он
CR8376A (es) Metodo para producir derivados de (3-oxo-2,3-dihidro-1 h-isoindol-1-il)-acetilguanidina
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
EA200602169A1 (ru) Способ получения производных 2-оксо-1-пирролидина внутримолекулярным аллилированием
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
CY1108156T1 (el) Στερεοεκλεκτικη συνθεση αναλογων βιταμινης d
HUP0103089A2 (hu) Beraproszt észter előállítása szelektív oxidációval
EA201300440A1 (ru) Способ получения (3s,3s') 4,4'-дисульфандиилбис(3-аминобутан-1-сульфокислоты)
EA199900948A1 (ru) Способ получения 2-арил-3-арил-5-галогенпиридинов, используемых в качестве ингибиторов cox-2
EA200801400A1 (ru) Новые производные индолизина, способ их получения и терапевтические композиции на их основе
NO20076139L (no) Fremgangsmate for a fremstille blekeaktivatorer
EA200970116A1 (ru) Кристаллический гидрохлорид неморубицина